Ipafricept

Drug Profile

Ipafricept

Alternative Names: Fzd8-Fc; OMP 54F28

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Class Antineoplastics; Disulfides; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Proteins; Recombinant fusion proteins
  • Mechanism of Action Frizzled 8 receptor modulators; Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatocellular carcinoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 10 Oct 2016 Efficacy and adverse events data from a phase Ib trial in Pancreatic cancer presented at the European Society of Medical Oncology (ESMO-2016) Congress
  • 07 Oct 2016 Adverse events and pharmacokinetics data from a phase Ib trial in Pancreatic cancer presented at the European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Aug 2016 Oncomed completes a phase-I clinical trial in Solid tumours (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in USA (IV) (NCT01608867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top